October 14, 2005



Ms. Robin Rasor

Director of Licensing

The University of Michigan

Office of Technology Transfer

3003 S. State Street, Suite 2071

Ann Arbor, MI  48109-1280



Attn:  File No. 1061



Dear Robin,



Pursuant to your meetings and discussions with Biomedical Diagnostics staff and me, and to reflect the current business forecasts, I am writing to request amendment to the License Agreement between Genesis Bioventures, Inc. and The University of Michigan (File No. 1061).



The following modifications in Section 5.3 (Milestones) are requested:



| | 1. | Milestone (2):  Characterization of target protein(s) based on verifiable protein sequence(s).
| | -- | ----------------------------------------------------------------------------------------------



We request the milestone date be moved from February 15, 2005 to December 31, 2005.



| | 2. | Milestone (3):  The filing of an FDA application for the current format OR Adoption of an improved alternate diagnostic format (such as ELISA).
| | -- | -----------------------------------------------------------------------------------------------------------------------------------------------



We request the milestone date be moved from May 15, 2005 to December 31, 2005.



| | 3. | Milestone (4):  Cumulative NET SALES of at least $350,000.
| | -- | ----------------------------------------------------------



We request the milestone date be moved from November 15, 2005 to December 31, 2006.



| | 4. | Milestone (5):  Cumulative NET SALES of at least $1,300,000.
| | -- | ------------------------------------------------------------



We request the milestone date be moved from November 15, 2006 to December 31, 2007.



| | 5. | Milestone (6):  Increased employee staffing levels from those on May 15, 2004, including a senior regulatory person, 5 scientists (including medical technicians) and a viable customer service function (the last of which may be contracted out).
| | -- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



We request the milestone be eliminated.



| | 6. | Milestone (7):  FDA approval of improved alternate diagnostic format (such as ELISA) OR FDA approval of current diagnostic format.
| | -- | ----------------------------------------------------------------------------------------------------------------------------------



We request the milestone and dates be reworded as follows:



FDA approval of current diagnostic format by December 31, 2008 OR FDA approval of

improved alternate diagnostic format (such as ELISA) by December 31, 2010.



Milestone (1): FIRST COMMERCIAL SALE by October 15, 2003 was completed on schedule as previously reported to you.





---







Ms. Robin Rasor

The University of Michigan

Office of Technology Transfer

October 14, 2005

Page 2 of 3





The following modifications in Section 3.1 (d) (Annual license maintenance fees) are requested:



| | 1. | We request that the due date for the annual fees be moved from the last day of June to December 31 of the years specified.
| | -- | --------------------------------------------------------------------------------------------------------------------------



| | 2. | We request that the annual license maintenance fees begin in 2007 instead of 2006. The annual license fee schedule would then be as follows:
| | -- | --------------------------------------------------------------------------------------------------------------------------------------------



| | (1) | In 2007:  $25,000;
| | --- | ------------------



| | (2) | In 2008:  $50,000;
| | --- | ------------------



| | (3) | In 2009 and in each year thereafter during the term of this Agreement:  $100,000.
| | --- | ---------------------------------------------------------------------------------





The following modifications in Section 3.1 (e) (Milestone payments) are requested:



| | 1. | Milestone payment 1): Twenty-five thousand dollars ($25,000) at time of characterization of target protein(s).
| | -- | --------------------------------------------------------------------------------------------------------------



We request that payment for this milestone be eliminated.



| | 2. | Milestone payment 2): Twenty-five thousand dollars ($25,000) at time of FDA filing or adoption of an alternate format.
| | -- | ----------------------------------------------------------------------------------------------------------------------



We request that payment be moved from at time of milestone achievement to within one year of milestone achievement and that LICENSEE may credit 100% of milestone payment due in full against royalties otherwise due MICHIGAN for the calendar year in which LICENSEEs milestone payment is due.



| | 3. | Milestone payment 3):  Twenty-five thousand dollars ($25,000) at time of reaching defined staffing levels.
| | -- | ----------------------------------------------------------------------------------------------------------



We request that payment  for this milestone be eliminated.



| | 4. | Milestone payment 4):  One hundred fifty thousand dollars ($150,000) at time of FDA approval.
| | -- | ---------------------------------------------------------------------------------------------



We request that payment be moved from at time of milestone achievement to $50,000 within one year and an additional $100,000 within two years of milestone achievement and that LICENSEE may credit 50% of milestone payment due in full against royalties otherwise due MICHIGAN for the calendar year in which LICENSEEs milestone payment is due.









---







Ms. Robin Rasor

The University of Michigan

Office of Technology Transfer

October 14, 2005

Page 3 of 3





Thank you for your consideration on these amendments. If you agree to these modifications, please indicate your approval below. Meanwhile, please contact me if you have any questions.





|Sincerely, | Signed and agreed:
|---------- | ------------------



|GENESIS BIOVENTURES, INC. | THE UNIVERSITY OF MICHIGAN
|------------------------- | --------------------------







|_________________________________ | _____________________________________
|--------------------------------- | -------------------------------------

E. Greg McCartney

|CEO/President | Printed Name: _________________________
|------------- | ---------------------------------------



| | Title:  ________________________________
| | ----------------------------------------



| | Date:  ________________________________
| | ---------------------------------------









CC:  James S. Arthurs, Biomedical Diagnostics, LLC